Lymphocyte activation gene-3 (LAG3) mRNA and protein expression on tumour infiltrating lymphocytes (TILs) in oesophageal adenocarcinoma

Florian Gebauer 1 · Max Krämer 2 · Christiane Bruns 1 · Hans A. Schlößer 1,4 · Martin Thelen 1,4 · Philipp Lohneis 2 · Wolfgang Schröder 1 · Thomas Zander 3 · Hakan Alakus 1 · Reinhard Buettner 2 · Heike Loeser 2 · Alexander Quaas 2

Received: 26 April 2020 / Accepted: 20 June 2020 / Published online: 26 June 2020 © The Author(s) 2020

Abstract
Purpose Lymphocyte activation gene-3 (LAG3) is an immunosuppressive checkpoint molecule expressed on T cells. The frequency and distribution of LAG3 expression in oesophageal adenocarcinoma (EAC) is unknown. Aim of the study was the evaluation and distribution of LAG3 on tumour infiltrating lymphocytes (TILs) and correlation with clinico-pathological and molecular data.

Methods We analysed tumor tissue samples using immunohistochemistry, multi-colour immunofluorescence and mRNA in-situ technology. The analyses were performed on a multi-spot tissue microarray (TMA) with 165 samples, followed by an evaluation on a single-spot TMA with 477 samples. These results were correlated with clinical and molecular tumour data.

Results LAG3 expression on TILs was detectable in 10.5% on the multi-spot TMA and 11.4% on the single-spot TMA. There was a strong correlation between protein expression and mRNA expression (p < 0.001) in TILs. LAG 3 expression was correlated with CD4+ and CD8+ T-cells within the tumor (p < 0.001). LAG3 expression showed an improved overall survival (OS) compared to patients without LAG3 expression (median OS 70.2 vs. 26.9 months; p = 0.046). The effect was even clearer in the group of patients with tumour stages > pT2 (70.2 vs 25.0 months; p = 0.037).

Conclusion This is the first description of LAG3 expression on TILs in EAC, underscoring the importance of immunomodulation in EAC. Our data suggest an impact of LAG3 in a relevant subset of EAC. Therapeutic studies investigating the efficacy of LAG3 inhibition in EAC will also provide predictive evidence and relevance of the immunohistochemical determination of LAG3 expression.

Keywords LAG3 · Immunohistochemistry · mRNA in-situ · Oesophageal adenocarcinoma

Abbreviations
CI Confidence interval
EAC Oesophageal adenocarcinoma
IgSF Immunoglobulin superfamily
IHC Immunohistochemistry
LAG3 Lymphocyte-activation-protein 3
MHC Major histocompatibility complex
OS Overall survival

Florian Gebauer, Max Krämer, Heike Loeser, Alexander Quaas contributed equally to this work.

Florian Gebauer, Max Krämer, Christiane Bruns, Hans A. Schlößer, Martin Thelen, Thomas Zander, Hakan Alakus, Reinhard Buettner, Heikefo Loeser, Alexander Quaas are members of Gastrointestinal Cancer Group Cologne (GCGC).

1 Department of General, Visceral, Tumour and Transplantation Surgery, University of Cologne, Kerpener Strasse 62, 50937 Cologne, Germany
2 Institute of Pathology, University of Cologne, Cologne, Germany
3 Department I of Internal Medicine, Centre for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Gastrointestinal Cancer Group Cologne GCGC, University of Cologne, Cologne, Germany
4 Centre for Molecular Medicine Cologne, University of Cologne, Cologne, Germany

© Springer
Introduction

Immunotherapy has grown to a rapidly advancing sphere of research on modern strategies for the treatment of cancer (Fridman 2017). A number of patients have already benefited from immune checkpoint blockades, and various drugs are currently under evaluation in clinical trials (Zhao and Subramanian 2018). In oesophageal adenocarcinoma (EAC)—a rapidly increasing cancer entity with a worse prognosis—surgery, chemotherapy and radiation remain the basis of treatment of EAC (Gore 2005; Grierson et al. 2017). The role of evolving immunotherapy has yet to be examined for EAC.

Immune checkpoints are a well-known form of immunomodulation, leading to a down-regulated immune response in the tumour microenvironment. Several of these checkpoints have been detected, such as programmed death cell protein 1 (PD-1), which is common and has occurred during the treatment of melanoma, non-small-cell lung cancer (NSCLC), renal cell carcinoma and urothelial carcinoma (Andrews 2017; Roberts 2017; Ma 2017). In addition to PD-1, lymphocyte activation protein-3 (LAG3) presents a targetable checkpoint, as can contribute to therapy strategies, including treatment of EAC.

LAG3 belongs to the immunoglobulin superfamily (IgSF) and is particularly displayed on several forms of T-lymphocytes (CD4+, CD8+, regulatory T-cells [Treg], tumour infiltrating lymphocytes [TILs]), as well as B-lymphocytes and dendritic cells (He 2016). LAG3 shares approximately 20% identity with the CD4 gene, and it binds to major histocompatibility complex 2 (MHC II) with greater affinity than CD4 (He 2016). The LAG3/MHC II complex on CD4+ cells negatively modulates T-cell activity and enhances antigen self-tolerance when displayed on CD8+ cells. Conversely, LAG3 binding to MHC II on Treg cells advances the suppressive effect on T-lymphocytes, enforcing the negative immune regulation effect of LAG3 (Andrews 2017). Studies have suggested that LAG3 is a negative regulator of T-cell activation and function, since the blockade of LAG3 on human CD4 clones resulted in enhanced proliferation, with an elevated production of IL-2, IL-4, IFN-γ and TNFα (Previte, et al. 2019; Goldberg and Drake 2011).

Analysis of LAG3 overexpression on TILs has revealed evidence for a pathological role, which involves down-regulating the immune response for various cancer entities, such as chronic lymphatic leukaemia, colorectal cancer, ovarian cancer, melanoma and hepatocellular carcinoma, leading to a worse prognosis in LAG3 positive malignancies (Shapiro 2017; Li 2013; Hemon 2011; Huang 2015; Chen and Chen 2014). Interestingly, and in contrast to these findings, recent studies in breast cancer patients showed a favourable outcome in LAG3 positive tumours regarding the overall survival (OS) of the patients, while other studies showed a worse prognosis in breast cancer (Sidaway 2017; Burugu 2017).

The aim of the present study is to assess the expression of LAG3 on TILs at the protein level, as well as the mRNA level, in EAC and correlate the expression profile with clinicopathological and molecular data and the prognosis of individual patients.

Material and methods

Patients and tumour samples

The formalin-fixed and paraffin embedded samples from 477 patients with EACs, who underwent primary surgical resection or resection after neoadjuvant therapy between 1999–2014 at the Department of General, Visceral and Cancer Surgery, University of Cologne, Germany, were analysed. The standard surgical procedures were laparoscopic or laparoscopic gastrolysis and right transthoracic en-bloc oesophagectomy, with intrathoracic oesophagogastrectomy, including two-field lymphadenectomy of mediastinal and abdominal lymph nodes, transhiatal extended distal oesophagectomy with transabdominal intrathoracic or cervical anastomosis as described previously (Holscher 2007). Patients with advanced oesophageal cancer (cT3), or lymph node metastasis in clinical staging, received preoperative chemoradiation (5-Fluouracil, cisplatin, 40 Gy) or chemotherapy. Follow-up data were available for all patients. Patient characteristics are given in Table 1. Depending on the effect of neoadjuvant chemo- or radiochemotherapy, there was a preponderance of minor responders, defined as having a histopathological residual tumour of ≥ 10% (Schneider 2008).

According to the suggestions of the international immuno-oncology working group for assessing TILs on solid tumours, we constructed a multi-spot tissue microarray (TMA) (Simon et al. 2005; Helbig 2016; Hendry et al. 2017a, b). Construction of the multi-spot TMA and immunohistochemical staining procedures were performed as previously described (Simon et al. 2005; Helbig 2016). In brief, tissue cylinders, with a diameter of 1.2 mm each, were punched from selected tumour tissue blocks using a self-constructed, semi-automated precision instrument and embedded in empty recipient paraffin blocks. For the multi-spot TMA (165 patients), up to 8 tumour spots were punched out of the tumour, 4 spots each from the surface and the invasion front. The 165 patients evaluated using the multi-spot
TMA were used as a test cohort. These data were statistically correlated with survival and molecular data, such as TP53 mutational status.

We analysed 312 additional patients using a single-spot TMA. For this TMA, one tissue core from each tumour was randomly punched out and transferred into a TMA recipient block. 4 μm sections of the resulting TMA blocks were transferred to an adhesive coated slide system (Instrumedics Inc., Hackensack, NJ) for immunohistochemistry (IHC). All procedures performed for studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration, and its later amendments, or comparable ethical standards.

**Immunohistochemistry**

IHC was performed on the TMA slides. The following antibodies were used for IHC studies: a rabbit IgG monoclonal antibody (clone D2G40; dilution 1:300; Cell Signaling Technology, Netherlands) was used for LAG3, a rabbit monoclonal antibody (clone SP7; dilution 1:50; Thermo Fisher Scientific, USA) was used for CD3 and a mouse monoclonal antibody (clone C8/144B, dilution 1:200; Dako/Agilent, USA) was used for CD8. All immunohistochemical staining was performed using the Leica BOND-MAX stainer (Leica Biosystems, Germany) according to the protocol of the manufacturer. The evaluation of immunohistochemical expression was assessed manually by two pathologists (AQ and HL). Discrepancies in the results, which occurred only in a small number of samples, were resolved by consensus review.

**Immunofluorescence multi-colour staining**

Immunofluorescence staining was performed on TMAs and whole section slides. Therefore, paraffin sections were deparaffinised and antigens were retrieved with EDTA at pH 8 (PT Module, Lab Vision Thermo Scientific). Slides were blocked using normal horse serum, for 30 min at room temperature (Vector Laboratories). Slides were incubated overnight at 4 °C with a master mix containing the primary antibodies: rabbit anti-LAG3 IgG monoclonal antibody D2G40, mouse anti-CD8 monoclonal antibody C8/144B, mouse anti-FOXP3 monoclonal antibody 236A/E7 (Abcam, UK; dilution 1:100), rabbit anti-CD4 monoclonal antibody 4B12 (Roche, Switzerland, ready to use). After conjugation with an antibody-bound enzyme (horseradish peroxidase or alcalic phosphatase), detection was carried out using DISCOVERY Silver kit (LAG3), DISCOVERY Yellow kit (FOXP3), DISCOVERY Teal kit (CD8), DISCOVERY Red Kit (CD4; all Ventana/Roche, Switzerland). Counterstaining was done with hematoxylin and bluing reagent.

**Strategy of evaluation**

LAG3: < 1% of lymphocytes was defined as negative, 1–2% of lymphocytes were assessed as “LAG3 low”, > 2% of lymphocytes was counted as “LAG3 high”. The reading strategy followed the assessment of LAG3 in clinical trials in malignant melanoma, where the response rates of the LAG3 blockade correlated with LAG3 expression of ≥ 1% (Ascierto and McArthur 2017). For statistical analysis, the cut off was determined as ≥ 1%, thus low and high LAG3 expression was assessed as positive and < 1% expression as negative.

CD3: CD3 expression in < 3 lymphocytes/mm² was evaluated as negative, > 3–50 lymphocytes/mm² were assessed as low positive and > 50 lymphocytes/mm² were defined as high positive, considering peritumoral and intratumoral distribution.

CD8: CD8 was analysed according to the CD3 evaluation criteria. For statistical analysis, high expression of CD3 or CD8 with > 50 lymphocytes/mm² were assessed as positive.

Regarding the multi-spot TMA considering eight tumor spots in total, four spots each of the tumour surface and the invasive margin, were examined. We calculated the average of the scores and matched the four samples to one category based on limit values: 0, negative; 0–0.9, low; 1–2, high (e.g. LAG3 expression in spot 1 = 2, spot 2 = 1, spot 3 = 0, spot 4 = 2, average of the spots: 1.25 → category “high”). Discrepancies in the results were resolved by consensus review.

| Table 1 | Baseline characteristics of the entire patient cohort |
|---------|------------------------------------------------------|
|         | Total | Percent (%) |
| Sex     |       |             |
| Female  | 42    | 10.0        |
| Male    | 379   | 90.0        |
| Age group |     |             |
| ≤ 65    | 221   | 52.4        |
| > 65    | 200   | 47.6        |
| Tumour stage |   |             |
| pT 1    | 50    | 11.9        |
| pT 2    | 36    | 8.6         |
| pT 3    | 322   | 76.8        |
| pT 4    | 11    | 2.6         |
| Lymph node status | |             |
| pN 0    | 161   | 38.3        |
| pN +    | 259   | 61.7        |
analysed using the log-rank test. Univariate and multivariate survival curves were plotted using the Kaplan–Meier method and Fisher's exact tests and displayed by cross-tables. Staining and clinical data were calculated using the chi-squared test. Statistical analyses were performed for prognostic factors of overall survival using the Cox regression model. All tests were two-sided. Values < 0.05 were considered statistically significant.

Results
Patient baseline characteristics

Patient characteristics are given in Table 1. A total of 421 patients with EAC that underwent surgical tumour resection were immunohistochemically interpretable. Reasons for non-interpretable cases included lack of tissue samples or absence of unequivocal cancer tissue in the TMA spot. Operative procedures were either thoraco-abdominal en-bloc oesophagectomy \( (n = 269, 63.9\%) \) with intrathoracic anastomosis or transthoracic oesophagectomy with transabdominal or cervical anastomosis \( (n = 152, 36.1\%) \). For the single-spot TMA, 42 patients \( (10.0\%) \) were female, 379 \( (90.0\%) \) male. A similar distribution was found for the multi-spot TMA \( (9.7\% \text{ female}, 90.3\% \text{ male}) \). The median age of the entire patient cohort was 65.2 years \( (range 33.6–85.6 \text{ years}) \) at the time of diagnosis. Neoadjuvant treatment \( (\text{chemo- or radiotherapy}) \) was administered to 271 patients \( (59.8\%) \) before operation from the single-spot TMA samples and 23 patients \( (13.9\%) \) from the multi-spot-TMA samples. The median follow-up for the entire cohort was 52.0 months.

LAG3 protein and mRNA expression

LAG3 immunostaining was localised in the cytoplasm/membrane of tumour infiltrating lymphocytes (Fig. 1). LAG3 expression of ≥ 1% was assessed as positive. In total, on the single-spot TMA, LAG3 positivity was detectable in 11.4% \( (n = 48) \) of interpretable EAC cases and 10.5% \( (n = 17) \) of the multi-spot TMA samples (Table 2). The latter demonstrated a heterogenic LAG3 distribution within the four spots of each patient, the invasive and the surface tumour margin, in 60.1% \( (n = 100) \). However, comparing the expression pattern of the surface with the invasive tumour margin, a low heterogeneity was observed, only one case \( (0.6\%) \) was positive for LAG3 on the surface and not on the invasive margin.

LAG3 mRNA expression was analysed in 77 patients from the multi-spot TMA and positive in 36 patients \( (46.8\%) \) on the surface margin and in 28 patients \( (35.9\%) \) on the infiltration margin. Compared to detection by IHC, LAG3 mRNA expression showed higher expression frequencies on both the surface and infiltration margins. Despite the higher total number of LAG3 positive samples, as determined by mRNA base scope, there was a strong correlation between IHC and mRNA detection \( (p < 0.001) \). On the surface margin, 77.1% of the LAG3 IHC negative patients showed no mRNA expression, and similar results were found for the
infiltration margin (85.7%). No patient in any of the groups exhibited detectable protein expression without the presence of mRNA expression. No correlation between TP53 mutations, HER2 overexpression and LAG3 expression was revealed ($p = 0.383$ and $p = 1.000$, respectively).

**CD3 and CD8**

The status of CD3 was evaluated on single- and multi-spot TMA; CD8 infiltrating T-cells were only evaluated on the multi-spot TMA. CD8 demonstrated a similar distribution pattern as CD3, but to a lesser degree. High amounts of CD3 TILs were associated with an improved OS compared to CD3 poor tumours (Fig. 2a). In both tumour regions, roughly half of the tumours presented with a high accumulation of CD3 TILs (luminal 49.1%, invasive front 51.5%), which was correlated in the cross-table analysis ($p < 0.001$). There was no difference between the surface and the invasive tumour margin with respect to the amount of CD3 TILs. CD3 distribution within the tumour was predominantly peritumoral ($n = 130; 78.8\%$) and showed no difference between the surface and the invasive tumour margin. High amounts of CD3 and CD8 TILs featured a strong correlation with high LAG3 expression ($p < 0.001$).

**LAG3 and co-expression of T-cell subset markers**

To evaluate which subtypes of T-cells expressed LAG3, we performed multicolour immunofluorescence and multicolour immunohistochemistry staining on two exemplary TMAs. In a semiquantitative analysis, we correlated LAG3 positive cases with the expression of CD3, CD4 and CD8 (Figs. 3 and 4). In normal lymphatic tissue, LAG3 is co-expressed with CD3, CD4 CD8 and FOXP3. In EAC multicolour immunohistochemistry, a predominant co-expression of LAG3 and CD8 was seen, only a minor fraction demonstrated positivity for LAG3 and CD4 or FOXP3.
In multicolour immunofluorescence LAG3 positive cells within the tumour microenvironment were seen with co-expression of CD3, CD4 and CD8.

**LAG3 as a prognostic biomarker**

To analyse the impact of LAG3 expression on TILs, Kaplan Meier survival analysis were performed on the single-spot TMA. The OS in patients with LAG3 expression significantly improved compared to LAG3 negative tumours. The
median OS was 70.2 months (95% confidence interval (CI) 1.9–138.5 months) in LAG3 positive tumours compared to a median OS of 26.9 months (95% CI 21.9–31.8 months, \( p = 0.046 \)) in LAG3 negative cases (Fig. 5a). The effect was independent of whether neoadjuvant treatment was administered or not. The observed survival difference in the entire patients’ cohort is predominantly driven by advanced tumour stages (> pT2). LAG3 positive tumours with tumour stages > pT2 had a median OS of 70.2 months (95% CI 20.6–32.0 months), while LAG3 negative tumours with tumour stages > pT2 showed a median OS of 25.0 months (95% CI 2.1–154.6 months) \( (p = 0.037) \). In the group of pT1/2 tumours, a LAG3 dependent survival difference could not be revealed (Fig. 5b and c). In a multivariate cox-regression model, LAG3 expression alone failed to serve as an independent prognostic marker due its correlation with advanced tumour stages (Table 3).

**Discussion**

In a large set of 421 patients with EAC, we report the impact of the checkpoint inhibitor LAG3 considering the protein and mRNA expression, as well as the distribution pattern within the tumour, in correlation with clinical and molecular data. In our cohort, LAG3 was positively correlated with subset of T-cells (predominant CD8 positive T-cells). Additionally, elevated LAG3 expression was linked to a significantly better outcome for patients in the advanced tumour stages subgroup.

The construction of the multi-spot TMA for the analysis of tumour heterogeneity and associated TILs followed the recommendations of the International Immuno-Oncology Biomarkers Working Group (Hendry et al. 2017a, b). We started our analysis with a test-cohort of 165 patients using the multi-spot TMA, followed by a much larger cohort considering additional patients to reassess the results found before. The multi-spot TMA demonstrated a heterogenic LAG3 distribution within the eight tumour spots; however, by comparing the tumour surface with the infiltration margin, we found a consistent expression pattern of LAG3.

**Fig. 4** Multicolour IHC for LAG3 (black signals), CD4 (red signals), FOXP3 (yellow signals) and CD8 (blue signals): a co-expression of LAG3, CD4 and FOXP3 in a minor fraction; b predominant co-expression of LAG3 with CD8 (inserted detail), here no relevant co-expression with CD4

**Fig. 5** a Tumours with LAG3 positive TILs showed a better overall survival. 70.2 months (95% confidence interval (CI) 1.9–138.5 months) in LAG3 positive tumours compared to a median OS of 26.9 months (95% CI 21.9–31.8 months, \( p = 0.046 \)) for LAG3 negative tumours. b In early invasive tumours, LAG3 dependent survival difference could not be revealed, the survival difference in the entire patients’ cohort is therefore driven by advanced tumour stages (< pT2) (c)
Thus, in the case of endoscopically taken biopsies LAG3 expression in EAC can serve as a reliable predictor regarding the overall LAG3 expression within the tumour.

In contrast to our initial hypothesis, we are able to show a favourable outcome of patients with elevated LAG3 in TILs. However, most probably due to a correlation with pT-stage and lymph node metastasis, the LAG3 expression failed to serve as an independent prognostic marker, since the survival benefit correlated with LAG3 expression was predominantly detectable in pT3/4 tumours. This is fully in line with recent studies on breast cancer patients but in contrast to previous results in other solid tumour entities, such as melanoma and hepatocellular carcinoma (Li 2013; Hemon 2011; Sidaway 2017). However, divergent descriptions concerning the prognostic impact of a single immune checkpoint between different tumour entities are well known and likewise given for PD-1/PD-L1 (Bertucci 2015, 2017). This phenomenon can be explained by various analysis techniques and antibodies or by different organic systems. Due to technical variabilities, we analysed the mRNA expression profile of LAG3 for 77 patients and compared it to the protein expression detected using IHC in a double-blinded examination. Since there was a distinct correlation between the mRNA and protein expression profiles of LAG3, we confirm the viability of our antibody and analysis techniques.

The favourable outcome in context with LAG3 expression appears to be counterintuitive, initially, considering the suppressive effect of this immune checkpoint. Furthermore, our distinct results require exploratory approaches to clarify the role of immunomodulation in EAC. We, therefore, developed hypotheses to explain how LAG3 overexpression could be related to a better outcome.

An elevated expression may be part of a powerful immune reaction leading to an effective antitumoral response. Thus, we assume that pro-inflammatory signalling pathways against the tumour could be compensatory regulation by the suppressive effect of LAG3. We found a strong correlation between the existence of T-cells (CD3) and LAG3, supposing that an inflammatory microenvironment is attended by increased LAG3. Since tumours with elevated T-cells showed a significantly better outcome in our cohort, we underline the importance of an inflammatory antitumoral response, which is in accordance with former studies on EAC (Noble 2016). We therefore presume that LAG3 serves as a biomarker for a strong immune response.

The initially assumed inhibitory immunomodulatory effect does not seem to be reflected by our current analysis to the extent expected. As described above, similar effects have been demonstrated for PD-L1 expression in different tumour entities. Whether a pharmacological LAG3 inhibition will prove to be effective in EAC cannot be conclusively answered on the basis of the available data. In our opinion, however, a positive effect of LAG3 inhibitor therapy can be assumed. However, further functional investigations with regard to LAG3 expression and interactions with tumour cells are necessary.

Taken together, we presume that LAG3 serves as a surrogate parameter in immunogenic tumour biology; although, we must admit that the limited knowledge of downstream mechanisms and the interaction with other intracellular pathways only allows us to hypothesise about a possible function of the protein in EAC. In addition, it remains obscure why only advanced tumour stages revealed a prognostic impact of LAG3 in contrast to early stages, underlining the urgent need for further research on immunomodulation.

Nevertheless, our assumptions support the use of LAG3 inhibition for EAC, since the loss of regulatory survival mechanisms would lead to a stronger immune response via CD3/8. Therapeutic studies investigating the efficacy of LAG3 inhibition in EAC will also provide predictive evidence on the determination of the LAG3 expression in the tumour microenvironment, as we have learned in the past for the determination of PD-L1 in lung cancer.

### Availability of data and material

The original data can be requested from the corresponding author, including SPSS tables and statistical syntax, immunohistochemical and rRNA data.

### Acknowledgments

Open Access funding provided by Projekt DEAL.

### Author contributions

FG: study conception, statistical analysis, manuscript writing, operation of patients, immunohistochemistry analysis; MK: immunohistochemistry and mRNA analysis, manuscript writing; CB: manuscript writing, manuscript revision, operation of patients; HAS: manuscript revision, immunofluorescence analysis; MT: immunofluorescence analysis; PL: manuscript revision, immunohistochemistry staining; WS: manuscript revision, operation of patients; TZ: manuscript writing, data analysis; HA: data analysis, operation of patients; RB: mRNA analysis, manuscript revision; HL: manuscript writing, immunohistochemistry and mRNA analysis, TMA construction; AQ:
TMA construction, immunohistochemistry supervision, manuscript writing, manuscript revision.

**Funding** Not applicable.

**Compliance with ethical standards**

**Conflict of interest** Reinhard Böttner: Co-Founder and Co-Owner of Targos Molecular Pathology Inc. Kassel/Germany. Hans Schösser: Funding for Research from Astra Zeneca for research outside this study. Thomas Zander: BMS: advisory board, clinical trial; Novartis: advisory board, clinical trial; Lilly: advisory board, clinical trial; MSD: advisory board, clinical trial. The remaining authors declare no conflict of interest or other financial disclosures.

**Ethics approval** The study was approved by the local ethics committee, due to the anonymised character of the study, individual consent of the patients was not requested.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

Andrews LP et al (2017) LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev 276(1):80–96

Ascierto PA, McArthur GA (2017) Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future? J Transl Med 15(1):173

Bertucci F et al (2015) PD1L expression is an independent prognostic factor in localized GIST. Oncuimmunology 4(5):e1002729

Bertucci F et al (2017) PD1L expression is a poor-prognosis factor in soft-tissue sarcomas. Oncuimmunology 6(3):e1278100

Bott M et al (2011) The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 43(7):668–672

Burugu S et al (2017) LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors. Ann Oncol 28(12):2977–2984

Chen J, Chen Z (2014) The effect of immune microenvironment on the progression and prognosis of colorectal cancer. Med Oncol 31(8):82

Fridman WH et al (2017) The immune contexture in cancer progression and treatment. Nat Rev Clin Oncol 14(12):717–734

Goldberg MV, Drake CG (2011) LAG-3 in Cancer Immunotherapy. Curr Top Microbiol Immunol 344:269–278

Gore RM (2005) Upper gastrointestinal tract tumours: diagnosis and staging strategies. Cancer Imaging 5:95–98

Grierson P, Lim KH, Amin M (2017) Immunotherapy in gastrointestinal cancers. J Gastrointest Oncol 8(3):474–484

He Y et al (2016) Lymphocyte-activation gene-3, an important immune checkpoint in cancer. Cancer Sci 107(9):1193–1197

Helbig D et al (2016) Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas. Oncotarget 7(16):21763–21774

Hemon P et al (2011) MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol 186(9):5173–5183

Hendry S et al (2017a) Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunoncology biomarkers working group: part 1: assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research. Adv Anat Pathol 24(5):235–251

Hendry S et al (2017b) Assessing Tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv Anat Pathol 24(6):311–335

Holscher AH et al (2007) Laparoscopic ischemic conditioning of the stomach for esophageal replacement. Ann Surg 245(2):241–246

Huang RY et al (2015) LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. Oncotarget 6(29):27359–27377

Li FJ et al (2013) Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8(+) T cell in HCC patients. Immunol Lett 150(1–2):116–122

Ma QY et al (2017) Function and regulation of LAG3 on CD4(+) CD25(-) T cells in non-small cell lung cancer. Exp Cell Res 360(2):358–364

Noble F et al (2016) Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma. Cancer Immunol Immunother 65(6):651–662

Previte DM et al (2019) Lymphocyte activation gene-3 maintains mitochondrial and metabolic quiescence in Naive CD4(+) T Cells. Cell Rep 27(1):129–141

Quaas A et al (2019) Genomic characterization of TP53-wild-type esophageal carcinoma. Transl Oncol 12(1):154–161

Roberts K et al (2017) Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities. Asia Pac J Clin Oncol 13(4):277–288

Schneider PM et al (2008) Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg 248(6):902–908

Shapiro M et al (2017) Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia. Haematologica 102(5):874–882

Sidaway P (2017) Breast cancer: LAG3 expression indicates favourable outcomes. Nat Rev Clin Oncol 14(12):712

Simon R, Mirlacher M, Sauter G (2005) Tissue microarrays. Methods Mol Med 114:257–268

Zhao X, Subramanian S (2018) Oncogenic pathways that affect antitumor immune response and immune checkpoint blockade therapy. Pharmacol Ther 181:76–84

**Publisher’s Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.